Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019
Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019'; Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - RIG-I (retinoic acid-inducible gene 1) is a RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is involved in viral double-stranded (ds) RNA recognition and the regulation of immune response. It acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.
The report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019' outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Hepatitis B, Solid Tumor, Breast Cancer, Lymphoma, Melanoma, Metastatic Liver Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors and Triple-Negative Breast Cancer (TNBC).
SCOPE
SUMMARY
According to the recently published report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019'; Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - RIG-I (retinoic acid-inducible gene 1) is a RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is involved in viral double-stranded (ds) RNA recognition and the regulation of immune response. It acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.
The report 'Probable ATP Dependent RNA Helicase DDX58 - Pipeline Review, H2 2019' outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Hepatitis B, Solid Tumor, Breast Cancer, Lymphoma, Melanoma, Metastatic Liver Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors and Triple-Negative Breast Cancer (TNBC).
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)
- The report reviews Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Overview
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Companies Involved in Therapeutics Development
Bioncotech Therapeutics SL
Kineta Inc
Merck & Co Inc
Sirenas LLC
Spring Bank Pharmaceuticals Inc
Vycellix Inc
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Drug Profiles
(inarigivir soproxil + tenofovir disoproxil fumarate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Agonize RIG1 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inarigivir soproxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-44 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-9400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLR-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Modulate RIG-I for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target RIG-I for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Dormant Products
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2019: Bioncotech Therapeutics phase I BO-112 data presented at ESMO Immuno-Oncology Congress 2019
Oct 17, 2019: Spring Bank announces interim top-line results from the first cohort of the phase 2 trial evaluating low-dose Inarigivir plus Vemlidy in Chronic Hepatitis B Patients
Oct 14, 2019: A Yale-developed drug shows promise as immune therapy for cancer
Jun 06, 2019: Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
Apr 12, 2019: Spring Bank announces positive results from the recently completed phase 2 chronic hepatitis B ACHIEVE Trial and additional Inarigivir studies
Apr 10, 2019: Spring Bank to host a conference call to discuss Inarigivir data presented at the International Liver Congress (EASL 2019)
Mar 28, 2019: Spring Bank announces Inarigivir abstracts accepted for oral and poster presentations at The International Liver Congress (EASL 2019)
Nov 09, 2018: Spring Bank announces additional Inarigivir results at AASLD Conference
Oct 09, 2018: Merck to present data on tumor drug candidate MK-4621 at ESMO 2018
Oct 03, 2018: Spring Bank announces Inarigivir data presentations at AASLD Conference
Aug 02, 2018: Spring Bank announces positive study results from the Inarigivir ACHIEVE trial
Apr 10, 2018: Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress
Mar 14, 2018: Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
Nov 15, 2017: Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
Oct 20, 2017: Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Overview
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Companies Involved in Therapeutics Development
Bioncotech Therapeutics SL
Kineta Inc
Merck & Co Inc
Sirenas LLC
Spring Bank Pharmaceuticals Inc
Vycellix Inc
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Drug Profiles
(inarigivir soproxil + tenofovir disoproxil fumarate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Agonize RIG1 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inarigivir soproxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-44 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-9400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLR-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Modulate RIG-I for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target RIG-I for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Dormant Products
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2019: Bioncotech Therapeutics phase I BO-112 data presented at ESMO Immuno-Oncology Congress 2019
Oct 17, 2019: Spring Bank announces interim top-line results from the first cohort of the phase 2 trial evaluating low-dose Inarigivir plus Vemlidy in Chronic Hepatitis B Patients
Oct 14, 2019: A Yale-developed drug shows promise as immune therapy for cancer
Jun 06, 2019: Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
Apr 12, 2019: Spring Bank announces positive results from the recently completed phase 2 chronic hepatitis B ACHIEVE Trial and additional Inarigivir studies
Apr 10, 2019: Spring Bank to host a conference call to discuss Inarigivir data presented at the International Liver Congress (EASL 2019)
Mar 28, 2019: Spring Bank announces Inarigivir abstracts accepted for oral and poster presentations at The International Liver Congress (EASL 2019)
Nov 09, 2018: Spring Bank announces additional Inarigivir results at AASLD Conference
Oct 09, 2018: Merck to present data on tumor drug candidate MK-4621 at ESMO 2018
Oct 03, 2018: Spring Bank announces Inarigivir data presentations at AASLD Conference
Aug 02, 2018: Spring Bank announces positive study results from the Inarigivir ACHIEVE trial
Apr 10, 2018: Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress
Mar 14, 2018: Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
Nov 15, 2017: Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
Oct 20, 2017: Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bioncotech Therapeutics SL, H2 2019
Pipeline by Kineta Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Sirenas LLC, H2 2019
Pipeline by Spring Bank Pharmaceuticals Inc, H2 2019
Pipeline by Vycellix Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bioncotech Therapeutics SL, H2 2019
Pipeline by Kineta Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Sirenas LLC, H2 2019
Pipeline by Spring Bank Pharmaceuticals Inc, H2 2019
Pipeline by Vycellix Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Bioncotech Therapeutics SL
Kineta Inc
Merck & Co Inc
Sirenas LLC
Spring Bank Pharmaceuticals Inc
Vycellix Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Bioncotech Therapeutics SL
Kineta Inc
Merck & Co Inc
Sirenas LLC
Spring Bank Pharmaceuticals Inc
Vycellix Inc
